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Abstract
Background: The overwhelming scarcity of organs within renal transplantation forces researchers and
transplantation teams to seek new ways to increase efficacy. One of the possibilities is the use of personalized
medicine, an approach based on quantifiable and scientific factors that determine the global immunological risk of
rejection for each patient. Although this approach can improve the efficacy of transplantations, it also poses a
number of ethical questions.
Methods: The qualitative research involved 22 semi-structured interviews with nephrologists involved in renal
transplantation, with the goal of determining the professionals’ views about calculating the global immunological
risk and the attendant ethical issues.
Results: The results demonstrate a general acceptance of this approach amongst the participants in the study.
Knowledge of each patient’s immunological risk could improve treatment and the post-graft follow-up. On the
other hand, the possibility that patients might be excluded from transplantation poses a significant ethical issue.
This approach is not seen as something entirely new, given the fact that medicine is increasingly scientific and
evidence-based. Although renal transplantation incorporates scientific data, these physicians believe that there
should always be a place for clinical judgment and the physician-patient relationship.
Conclusions: The participants see the benefits of including the calculation of the global immunological risk within
transplantation. Such data, being more precise and rigorous, could be of help in their clinical work. However, in
spite of the use of such scientific data, a place must be retained for the clinical judgment that allows a physician
to make decisions based on medical data, professional expertise and knowledge of the patient. To act in the best
interests of the patient is key to whether the calculation of the global immunological risk is employed.
Background
The present day overwhelming scarcity of organs for
renal transplantation forces researchers, transplantation
teams and national organizations responsible for alloca-
tion of organs to find new ways to resolve this issue.
The growing reliance on living donors is one approach
to easing the shortage [1], as is the establishment of
new protocols, such as the removal of organs from a
donor who has died after cardio-respiratory arrest [2],
or the acceptance of altruistic donation [3,4]. There is
another consequence of this organ scarcity: it
encourages those involved in transplantation to make
the best use of the resource. An ethical tension is thus
created between two principles: promoting equity (giv-
ing everyone a chance to have access to transplantation),
or maximizing efficacy (allocating organs to those recipi-
ents who would benefit the most). The criteria devel-
oped for the allocation of organs, which differ from one
country to the other [5,6], attempt to reconcile this ethi-
cal tension. With the goal, always, of focusing on the
best use of the resource, in order to increase the efficacy
of renal transplantation recent scientific research is now
focused on developing an approach based on persona-
lized medicine.
Personalized medicine, arising from pharmacoge-
nomics, is based on the premise: “the right treatment
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direct the most appropriate medical interventions,
choice of medications and preventive measures to a
patient, related to quantifiable data from differing fields,
by their genetic, clinical, psychosocial or other. This
type of medicine even enables the specification of indivi-
dual risks [8]. Most of the medical specialties, particu-
larly oncology [9], are interested in personalized
medicine. Transplantation medicine has recently joined
them. Research has shown that their immunological and
genetic characteristics predispose recipients to respond
differently to immunosuppressive treatment after a graft
[10,11]. For solid organs grafts, the precise and global
identification of the genes and proteins involved in
rejection enables specification of the potential immuno-
logical and genetic risks of rejection for each recipient,
in addition to precise determination of the markers of
survival for organs and grafts [12,13].
The Interdisciplinary Research Group on the Predic-
tors of Immunological Risk, financed by the Fonds de la
recherche en santé du Québec (FRSQ), is attempting to
put in place a scientifically precise method for determin-
ing the global immunological risk (GIR) of rejection for
each patient waiting for a renal transplant. This group
of researchers has actually shown that the levels of
genetic expression in the hematopoietic cells of the
donor can predict the risk of graft versus host disease in
bone marrow transplant cases [11]. Certain genes can
thus be used to predict alloreactivity and rejection. In
addition to these biological factors, others also play a
role in the risk of rejection, particularly immunological,
clinical and psychosocial factors [14,15]. Together, these
factors (biological, immunological, clinical and psycho-
social) could help to determine and to scientifically
quantify the GIR of rejection for each potential recipient
waiting for transplantation. This research methodology
is in line with the approach of personalized medicine,
since it facilitates identification of the best treatment for
a patient, as well as the associated risks.
The precise determination of the GIR based on perso-
nalized medicine could effect huge changes to medical
practice in renal transplantation. On the one hand, a
personalized medicine approach could help to adapt the
immunosuppressive therapy for each patient, and to pre-
dict more precisely each recipient’s risk of rejection.
Determination of the GIR could also help to improve
treatment and follow-up, more accurately predict the
outcome of a graft, and diminish the risks of organ
rejection; this indeed is the goal of the research group.
On the other hand, evaluation of the GIR could also
be used at the pre-graft stage to select recipients waiting
for transplantation, even to play a role in the allocation
of organs, revealing a utilitarian use of the GIR. This
new method thus arouses numerous ethical questions.
What are the benefits and the limits related to the use
of this new method? How should decisions be made
about its appropriate use? Does this approach constitute
an entirely new approach? What are its impacts on clin-
ical judgment and on the physician-patient relationship?
What are the related ethical concerns? It is important to
address these questions in concert with the perceptions
that clinicians have concerning them, since they are the
ones who will use the tools of personalized medicine.
The Interdisciplinary Research Group on the Predic-
tors of Immunological Risk has thus carried out a quali-
tative research project focused on the predictors of
immunological risk, in order to study the perceptions of
those involved in renal transplantation (transplanting
nephrologists and referring nephrologists) in the Pro-
v i n c eo fQ u e b e cr e g a r d i n gt h eu s eo ft h eG I Rb a s e do n
a personalized medicine approach. This group has pro-
vided responses to the questions underlying this
research, and has made possible a careful examination
of the various perspectives of those involved in renal
transplantation, from the viewpoint of scientific
medicine.
Methods
The participants chosen were nephrologists involved in
patient selection and working in a renal transplantation
centre in Quebec (transplanting nephrologists), or Que-
bec physicians specializing in nephrology and referring
patients to a transplantation centre for a renal graft
(referring nephrologists). The characteristics of the par-
ticipants are summarized in Table 1. The research ethics
committee of the University of Montreal has approved
this research, and all of the participants have given their
free and informed consent. Twenty-two semi-structured
interviews were conducted with the participants between
June 2007 and July 2008. The semi-structured interviews
were used in order to discern the views of participants
about the use within renal transplantation of the GIR
based on personalized medicine. Each interview began
with the presentation of short vignettes illustrating fic-
tional clinical cases based on whether patients with spe-
cific medical conditions such as diabetes, the presence
of genetic or immunological factors of rejection, would
be accepted on the transplant waiting list. The vignettes
were constructed based on discussions with transplant
nephrologists and observation in a renal transplant
team. One of these vignettes presented the definition of
personalized medicine given to the participants: “Perso-
nalized medicine attempts to prescribe a therapy or an
intervention for a specific patient, based on quantifiable
information from a number of different domains,
including the biological and the clinical. The use of the
tools of personalized medicine could play a role in the
assessment of patients for renal transplant by
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patients”. The use of vignettes in qualitative research
attempts to determine perceptions, attitudes and moral
values, particularly pertinent for this study [16]. Open-
ended questions were then directed to the participants.
The number of semi-structured interviews was sufficient
to attain the saturation and diversification of data [17],
for both the transplanting and the referring nephrolo-
gists. The semi-structured interviews were all recorded;
their average length was close to 60 minutes.
The transcription of the semi-structured interviews was
qualitatively analyzed using the content and thematic ana-
lysis method described by Miles and Huberman [18]. A
QSR N’Vivo (version 2.0) software was used to conduct a
qualitative analysis in order to identify emergent themes,
as well as the views of the participants. An independent
researcher coded 10% of the raw data, and the rate of cod-
ing agreement was subsequently assessed (84%).
Results
This section presents the different categories of the
results: the views of participants about the GIR as a tool
of personalized medicine, the benefits and limitations of
such an approach, the perceived ethical issues associated
with the GIR, and the perceived impacts on clinical
judgment and the physician-patient relationship. Some
of these themes, such as the benefits and limits of the
approach, the impacts on clinical judgment and on the
physician-patient relationship, clearly have an ethical
component, but were not labeled as such by partici-
pants. The difference between these themes and the sec-
tion on the perceived ethical issues, is that the latter is
focused on physicians’ answers to a specific question
during the semi-structured interviews (ie. their views
about what, for them, are the important ethical issues to
consider when using the GIR in patient selection within
renal transplantation).
Views of participants about GIR as a tool of personalized
medicine
The GIR based on personalized medicine is primarily
seen as a tool to assist clinicians in their work. This
approach is also seen as being objective, quantifiable
and scientific; however the participants are very skepti-
cal about attaining a high degree of precision in the eva-
luation of a patient’s risk of rejection, in spite of the
method’s precision.
“Id o n ’t believe that we would ever have criteria that
would discriminate well enough to be useful. This
would give a low percentage: 1, 2, 3, 4, 5, 6%” (P19).
Regarding the clinical use of the GIR, a majority of the
participants are in favour, as is shown in Table 2. How-
ever several participants mention more negative aspects,
such as the difficulty of applying the method in the
clinic, and the difficulty of accurately predicting the risk
of rejection.
“There could be no objective method that would, with
100% accuracy, predict what is going to happen. There
is no single objective method that could take into con-
sideration all the characteristics” (P21).
The GIR is determined in relation to quantifiable fac-
tors: biological, immunological, clinical and psychosocial.
Close to 68% of the participants mention that the factors
must be weighted, and that they don’ta l lh a v et h es a m e
influence, as is shown in Table 3. Also, the factors must be
determined in two ways: either in relation to the patient’s
Table 1 Characteristics of the 22 participants in the
research
Demographic characteristics Respondents
(n)
Respondents
(%)
Medical specialty
1. Transplant physicians
(nephrologists)
12 54.55
2. Referring nephrologists 10 45.45
Gender
1. Male 10 45.45
2. Female 12 54.55
Milieus
1. Adult 19 86.36
2. Paediatric 3 13.64
Age
1. 30-39 8 36.36
2. 40-49 2 9.09
3. 50-59 7 31.82
4. 60-69 5 22.73
Years of practice
1. 0-9 8 36.36
2. 10-19 3 13.64
3. 20-29 6 27.27
4. 30-39 5 22.73
Place of practice according to
population
1. 0-99 000 2 9.09
2. 100 000-499 000 4 18.18
3. 500 000-999 000 2 9.09
4. 1 000 000-2 999 000 14 63.64
Table 2 Views of the participants about the use of GIR
in renal transplantation
Perceptions Respondents (n) Respondents (%)
Favorable 22 100.00
Unfavorable 14 63.64
Neutral 3 13.63
In general, all of the participants are favorable to the calculation of the GIR,
although 14 mention both neutral and favorable views, while 3 mention both
favorable and negative views.
Dion-Labrie et al. BMC Medical Ethics 2010, 11:5
http://www.biomedcentral.com/1472-6939/11/5
Page 3 of 10situation or in relation to scientific models. The partici-
pants have not been explicit about ordering the impor-
tance of the factors, however they do give preference to
biological, clinical and immunological factors based on
objective data that can be verified using medical or scienti-
fic tests. The psychosocial factor is slightly different, but
just as important as the other three, since it also contri-
butes to the success of the graft [12,13]. It must be
included in the GIR, especially if it helps to determine
patient non-compliance, in spite of the difficulty of quanti-
fying this more subjective factor.
“Every factor is different. You can’t say: each is worth
10 points. It doesn’t work that way. The refusal to take pills
can’t be compared with having a risk of rejection” (P6).
“It is certain that for any given patient, one of these
factors will generally have more importance than the
others” (P15).
“So if the older predictive models have already shown
us that, for example, the psychosocial factors are less
important than the immunological factors, that is good -
I would weight them similarly” (P9).
The novelty of the method is an important element in
the participants’ views about the GIR. The use of a per-
sonalized medicine approach in transplantation should
not be regarded as something entirely new. The criteria
mentioned in the GIR are already used in transplanta-
tion, without precise weighing. The use of personalized
medicine is viewed as an extension of the existing prac-
tice of renal transplantation.
“Establishing the risk is an exercise that is carried out
with each patient. So there is nothing new in this
approach” (P5).
Benefits and limitations of the GIR in renal
transplantation
Figures 1 and 2 present the principle benefits and lim-
itations of the use of the GIR. The principle advantage
is the assistance that this approach gives to physicians
in their decision-making, by consolidating their impres-
sions and supporting their decisions. This is followed by
the possibility of offering a therapeutic goal for each
patient, and by the precision as well as the accuracy of
the method. The possibility that patients will make a
more informed choice, the assurance of a better follow-
up, and a greater objectivity are also important
advantages.
“I think that this will help us to make decisions which
sometimes, in the absence of data, are based on exper-
tise, or experience, or on ‘gut feeling"’ (P4).
Table 3 Weighting of the 4 factors involved in
calculating the GIR
Weighting of the factors Respondents
(n)
Respondents
(%)
Data are equal 8 36.36
Data are not equal 15 68.18
Depends on the situation, the
context
6 27.27
Depends on scientific factors 7 31.82
Figure 1 Benefits of the GIR in Renal Transplantation. Figure 1 indicates the main benefits, expressed in percentages, of the use of the GIR
within renal transplantation mentioned by the participants. The percentage for each benefit corresponds to the number of times each of these
was mentioned by the participants.
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that there is a greater chance of rejection, certainly the
follow-up and the treatment will perhaps not be the
same as with someone whose risk is low” (P14).
“The advantage of this method is the attempt to bring
a little more precision, clarity and accuracy” (P5).
The GIR also has its limitations, and raises concerns.
The main limitation is the possibility that patients will
not be accepted for a graft if their GIR is too high.
“But if one uses the data to say: ‘this person can be
grafted, the other cannot’ - this, I believe is a problem,
unless the factors reveal that the graft will definitely fail”
(P15).
There are other difficulties associated with this
approach: the difficulty of quantifying each of the fac-
tors, particularly the psychosocial and the global risk;
the physician’s loss of autonomy in whether or not to
accept a patient on the waiting list for transplantation;
loss of the human aspects of the physician-patient rela-
tionship and of the total picture of the patient.
“The risk is difficult to quantify. I don’tt h i n kt h a tw e
will ever be able to quantify a risk so precisely that we
would be able to foresee perfectly the results of a trans-
plantation” (P5).
“There is also the question of what takes place in your
conversation with the patient. There is also a place for
feeling. But the more precise the tool, the more one
loses in these areas, while gaining in objectivity” (P11).
The perceived ethical issues associated with the GIR
The participants point out several ethical concerns asso-
ciated with the approach based on personalized medi-
cine. Equity in the access to transplantation is an
important ethical issue. A balance must be attained
between efficacy and equity in the access to a graft
within a context of scarcity. A second important ethical
issue is the possible exclusion of patients because their
risk of rejection is too high. The GIR can be used to
help patients have access to transplantation by working
on their risk, but it could also be used to select patients
for renal transplantation in relation to whether their
GIR is low or high.
“It is certain that with these tools, perhaps 98% of
those grafted will have 10 good years with their graft.
But perhaps we would have grafted only 75% of those
we normally graft” (P7).
The participants mention as well that the establish-
ment of an entirely new medical technology must be
done in the interests of the patient. The establishment
of this approach in the clinic must be very carefully
evaluated, notably in relation to its impact on patients.
“I would be interested to see how things would change
after 6 months to one year of use. Will this have chan-
ged the decision-making and what will be the repercus-
s i o n sf o rt h ep a t i e n t ?W i l lt h e r eb eas u i c i d ed u et o
discouragement related to being taken off the list, or on
the other hand, will there be gratitude? This is what
Figure 2 Limitations of the GIR in Renal Transplantation. Figure 2 presents the main limitations, expressed in percentages, of the use of the
GIR within renal transplantation mentioned by the participants. The percentage for each limitation corresponds to the number of times each of
these was mentioned by the participants. The main limitation is lack of access to a graft; followed by the difficulty of the risk associated with
each of the 4 factors; the difficulty of quantifying criteria considered more subjective (psychosocial and clinical), particularly for specific patients;
the difficulty of calculating the global risk; as well as physician loss of autonomy through use of the GIR, and the loss of the human side with
this approach.
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than harming them” (P6).
Another ethical issue is who (physicians, patients, ethi-
cists or society) should decide to establish personalized
medicine in the clinic. The role of the physician should
be minor in the taking of this decision. The participants
grant a rather large place in this situation to the ethicist,
who is recognized, according to one participant, as the
moral authority for contemporary medicine.
“I think that the physician’s place in this discussion is
to present the data. What use is made of it, in my view,
is not up to the physician” (P10).
The perceived impacts on clinical judgment
Table 4 clearly indicates that, according to the respon-
dents, clinical judgment will continue to play an impor-
tant role in medicine, in spite of the increasing
introduction of scientific data. This clinical judgment
can be modified by the data which support the judg-
ment of the clinician. Furthermore, close to 65% of the
respondents mention that in the event of a discrepancy
between the scientific data provided by personalized
medicine and clinical judgment, the latter must take
precedence.
“It is absolutely necessary to modify the latter, because
when I look back just on the developments I have
experienced, lets say for 30 years, there are things I do
today that were not done earlier, because the means are
available, from the immunological point of view, that
were not available earlier” (P8).
“I imagine that my judgment will take the data into
account! I should hold to my own judgment” (P17).
The perceived impacts on the physician-patient
relationship
The participants are divided on the question of whether
the introduction of a personalized medicine approach is
going to change the physician-patient relationship. Half
of the participants think that there would be no change,
as Table 5 indicates. One third of the participants think
that the physician-patient relationship will change, parti-
cularly with the introduction of scientific data. The
changes could be both positive (more informed choice
for the patient, assistance in the decision-making for the
physician), or negative (diminishing the role and the
autonomy of the physician, patient resentment of
the physician in the event of exclusion). Finally, about
13% of the participants believe that any change in the
physician-patient relationship depends on the physician,
on the patient, and on what uses are permitted for the
GIR.
“I think that if the relationship is basically good, it will
not matter whether it is a scale that tells me that a
p a t i e n ti sa tr i s k ,o rw h e t h e ri ti sm yo w no p i n i o n ”
(P14).
“Some patients always want to have more, and to
know more. They will probably appreciate having access
to data that is perhaps less “up in the air,” while other
patients will not be at all interested” (P4).
A majority of the participants mention that using the
GIR would make it easier to tell patients that they can-
not be grafted. This approach helps to justify a refusal
to graft.
“T h e r ea r eg o i n gt ob em o r ee l e m e n t sw i t hw h i c ht o
deal. But I want to say that it is never easy to refuse
patients. But perhaps our decision-making is going to be
easier, since we will have more information” (P20).
Discussion
Views on GIR as a tool of personalized medicine
The participants are favorable to the use of the GIR as a
tool of personalized medicine, based on quantifiable fac-
tors, particularly given the goal of adapting post-graft
treatment and working on patients’ risks so that they
would have access to a renal transplantation. With this
approach, the more objective factors, such as the biolo-
gical and the immunological, are considered to be the
most important, even though markers for the latter are
already used to match an organ with a recipient [19].
According to the respondents, the clinical factor is
mainly considered to be an objective factor, based on
medical tests that evaluate the patient’so v e r a l lh e a l t h
status. It can also be seen as straddling the objective
and the subjective. In fact, with a view to a graft, a
patient’s health status is evaluated by a transplanting
nephrologist; and the impressions of the patient’sp h y s i -
cian also play a role in the clinical evaluation.
However, regarding the clinical situations presented in
the vignettes, it was difficult for the participants to
visualize the GIR’s calculation and grouping together of
the four quantifiable factors,s oc o n t r a r yt ot h ec u r r e n t
method which tends to separate the clinical and the psy-
c h o s o c i a l .T h ep a r t i c i p a n t sh a v ead e f i n i t et e n d e n c yt o
separate the data in the new method. They view them
as quite unrelated, rather than imagining the data com-
bined in order to calculate a global risk of rejection.
Table 4 Displacement of clinical judgment by the GIR based on personalized medicine
Displacement of the clinical judgment Respondents (n) Respondents (%)
Personalized medicine will displace clinical judgment 1 4.55
Personalized medicine will not displace clinical judgment 21 95.45
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each of the factors of individual risk.
According to some participants, only the biological
criteria are new in this approach.
The possibility of the GIR being used to deprive
patients of a renal graft poses a problem, unless there is
a 100% chance of rejection. The goal of the pre-trans-
plant evaluation is to improve the patient’sq u a l i t ya n d
duration of life through transplantation and not to
refuse access to a graft. Thus the participants question
such use, especially if the patient realizes that while the
use of the GIR has meant his being refused for renal
transplantation, he would have been accepted by the
current method. Refusing transplantation, based on
genetic factors, also arouses concerns. These predictors
of rejection do not depend on the willingness of the
patients. Unlike psychosocial or clinical factors, neither
the patient nor the medical team can do anything about
this type of risk. The patient is not responsible for hav-
ing genetic markers for rejection. This possible exclu-
sion related to taking biological factors into account can
also be seen as genetic discrimination in access to health
resources, a theme which is not highlighted in this
research, since legal protection against such discrimina-
tion already exists [20].
Novelty of the method, importance of clinical judgment
and the physician-patient relationship
The respondents do not believe that personalized medi-
cine is such a novelty. It fits into the continuum of Wes-
tern scientific medicine initiated by Francis Bacon (1560-
1626). Bacon believed that science is a useful tool that
enables modern medicine to prolong life and cure illness
[21]. The introduction of scientific and objective data in
medicine is in line with this ideal of an effective and effi-
cient medicine seeking above all to relieve patients’ suf-
fering [22,23]. Moreover, the clinicians perceive that
medical practice in renal transplantation is often perso-
nalized already. At the present time, a patient’s medical
evaluation for a possible renal transplantation seeks to
identify the patient’s risks of rejection based on clinical,
immunological and psychosocial data [24,25]. On the
other hand, the data is not quantified as it is in the
approach based on personalized medicine.
It is also interesting to note t note note hat, for the
participants, in spite of the inclusion of scientific and
quantifiable data within medicine, clinical judgment
remains important. It is humans who judge and assess
the data and make final decisions about the treatment
of patients, taking into account their knowledge of the
patients. According to the respondents, no computer
could achieve such an evaluation, based as it is on both
objective and subjective factors. Clinical judgment essen-
tially entails experience, intuition, feeling, and knowl-
edge of the patient; it plays a role in the interpretation
of data. Clinical judgment betokens a practical wisdom
stemming from training and professional practice [26].
This judgment is involved in the relationship between
the patient and the physician, as is dialogue, a commu-
nication between two players who seek the patient’s
good [27,28]. The participants believe that trust between
the physician and the patient is the foundation of this
relationship, which is complex in transplantation, since
there are so many healthcare personnel involved with
the patient (several specialists, psychologist or social
worker, the transplantation team that decides whether
or not a patient should be accepted for a transplanta-
tion, etc.). The addition of scientific data might intro-
duce changes, but the relational aspect remains. Precise
and thorough data will be given to the doctor and the
patient, so that a shared decision can be taken. If clinical
judgment retains its importance in this area, physician
autonomy will not be diminished by the reference to
scientific data. Physician interpretation of a patient’s
medical situation is crucial. More science within medi-
cine does not necessarily lead to a loss of physician
autonomy, deterioration of the physician-patient rela-
tionship or the clinical judgment.
Importance of the principle of beneficence in the
use of GIR
In their responses, the participants also highlight, some-
times implicitly, that the principle of beneficence is at
the heart of their judgment. A physician must act in the
best interests of the patient, and contribute to his/her
wellbeing, as the Hippocratic Oath states: “I will apply
dietetic measures for the benefit of the sick according to
my ability and judgment; I will keep them from harm
Table 5 Changes in the physician-patient relationship related to the use of the GIR
Changes in the physician-patient relationship related to
personalized medicine
Respondents (n) Respondents (%)
Yes, the relationship will change 7 33.33
No, the relationship will not change 11 52.38
It will depend on the physician, the patients and the use made of the approach
based on personalized medicine
3 14.29
No response 1 4.55
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patient’s own risks, in order to facilitate access to renal
transplantation, a clinician acts in the interests of the
patient. On the other hand, if the data indicate that
rejection is virtually assured, the physician would recog-
nize that this must be taken into account, so that the
patient’s life would not be unnecessarily put at risk, par-
ticularly since dialysis, an alternate treatment, is
available.
According to the participants, acting in the best inter-
ests of the patient tends to bring together two schools
of thought usually seen as opposed: patient-centered
medicine and scientific medicine [30]. Patient-centered
medicine is based on the claim that patients must be
active participants in their care [31,32]; while scientific
medicine, mainly represented by the evidence-based
paradigm, aims to base medical decision making about
the care of an individual patient on the best possible
evidence provided by scientific research [33]. In fact, as
was noted above, the GIR must be used in the best
interests of the patient. This implies that the partici-
pants, in order to build good relationships, must take
into consideration the patient’s story and his/her prefer-
ences; but it also implies that only medical treatment or
intervention based on the best scientific information
available will be offered. Patient-centered medicine and
scientific medicine are thus intrinsically linked in the
use of the GIR within renal transplantation.
Who decides about the use of GIR?
A ni m p o r t a n tq u e s t i o na r i s e si nr e l a t i o nt oh o wp e r s o -
nalized medicine is used: who must make decisions
about its use? This question was a vital ethical issue for
the participants. They did not feel that the physicians
should decide on their own to use personalized medi-
cine; the decision was one for society to make, based on
its values and its priorities for transplantation. This view
can be explained by the necessary involvement of the
members of a society in instituting a system for allocat-
ing organs. Such a system is based on gift and on soli-
darity. If no one in society is willing to donate organs,
whether during life or after death, the field of organ
transplantation could not exist. Given such essential
involvement, society has a right to make decisions about
the graft of organs. However, several referring nephrolo-
gists also mention that the choice of whether or not to
use the GIR must be left to the patients. Moreover, in
accordance with the ideal of efficient medical practice,
once a decision has been made to use this approach, it
must be in line with the best scientific data on the
subject.
It is interesting to note the crucial role in this that the
participants assign to ethicists. As mentioned in the
results, ethicists are viewed as being the moral arbiters
within medicine. They encourage ethical reflection, and
assist in resolving problematic situations, but are also
perceived as those who suggest the most appropriate
behavior, and the best course of action to follow. They
are granted great authority in decision-making.
Although the context is different, the respondents’ posi-
tion can be illustrated by the view of John Evans in his
book, Playing God, focused on genetic engineering.
Evans indicates how scientists have made bioethicists
the experts for controversial questions in the biomedical
sciences [34].
The participants’ perception of the role of the ethicist
can be questioned. Is the ethicist the initiator of moral
norms? Can he/she impose behavior and alone reflect
on the ethical problems linked to scientific develop-
ment? In a sense, the respondents would like their
choice of whether or not to use personalized medicine
to be in line with “aiming at the good life with and for
others in just institutions” [35]. In order to carry this
out, they give a central role to the ethicist. Nevertheless,
the establishment of moral norms, guidelines, and opi-
nions is above all society’s responsibility, and not that of
the ethicist. From the beginning in dialysis, members of
the community were involved in choosing the criteria
for patient selection [36]. When new policies were cre-
ated for organ allocation, far-reaching societal consulta-
tions usually took place [37,38]. Such choices are thus
political. If the ethicist has a role to play, it would
appear to us to differ from the one mentioned by the
participants. The ethicist must be seen more as a cata-
lyst who enriches the ethical reflection and promotes
public discussion. So the rol ed i f f e r sf r o mt h a tp l a y e d
when confronted by a specific case, when recommenda-
tions can be offered about “what to do in order to do
the right thing?” On the other hand, as soon as political
issues that concern the whole populace arise, the ethicist
cannot act alone. In order to come to an ethical and
political consensus, everyone’s involvement must be pro-
moted (citizens, politicians, those involved in the health-
care field).
Balancing equity/efficacy in renal transplantation
and the use of GIR
Another important ethical issue is finding a fair balance
between equity, which means providing access to renal
transplantation to those needing the resource, and effi-
cacy [39]. In fact, seeking to improve the efficacy of the
graft can contribute to limiting access, thus lessening
equity, since fewer patients would be grafted. The
method based on calculating the GIR could thus easily
correspond to a purely utilitarian view of transplantation,
which the participants reject. In their view, this method
must not involve giving organs only to those who have
no risk of rejection. To improve the efficacy of a graft
Dion-Labrie et al. BMC Medical Ethics 2010, 11:5
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sonalized medicine approach is used in the interests of
the patient. Determining a patient’s GIR must enable the
medical team to work to diminish this risk so that the
patient would benefit from transplantation and so that
the graft would last as long as possible. In this way, equity
would not be affected by efficacy, and might even be
improved. Some participants suggest that another way of
viewing the equity/efficacy dilemma is to see it as the
opposition between individual and collective rights. As in
all other areas of health care, access to transplantation
could be seen as a right [40]. In improving efficacy, the
individual’s right to access to a graft could be threatened
if the GIR is used to select patients at low risk, rather
than grafting all patients and then adjusting the immuno-
suppressive therapy. On the other hand, collective rights
can be more carefully addressed by assuring a better effi-
cacy for transplantations and better organ management.
T h e s er e m a r k si n d i c a t eac h a n g ei no u rv i e wo ft r a n s -
plantation: it has become a right, no longer a privilege
[36]. The flourishing of individualism and civil rights that
characterized the 1960’s could explain this change of ter-
minology and of vision.
Conclusions
I sp e r s o n a l i z e dm e d i c i n eaw a yo ft h ef u t u r ei nr e n a l
transplantation? The participants in this research believe
that it is, and a majority of them are in favour of it, in
spite of no consensus on the uses of this new approach.
This method, viewed as a tool, is thought to be thor-
ough, quantifiable and scientific. However, the partici-
pants do not view it as a novelty, but as part of a
continuum designed to make medicine more scientific,
efficacious and efficient. This approach improves physi-
cian’s decision making, and adaptation of the therapy
for each patient. On the other hand, there are doubts
about how precisely the GIR can be quantified with this
approach. Its principle limitations are the possibility of
excluding patients, as well as the difficulty of quantifying
t h eg l o b a lr i s ka n dt h ef a c t o rs considered more subjec-
tive (psychosocial). The factors that are quantified with
this approach must not be seen as equal, and they must
be weighted in relation to the patient’ss i t u a t i o no r
scientific models.
The development of personalized medicine poses great
challenges to clinical practice in renal transplantation.
An ethical reflection is essential regarding the method’s
possible exclusion of patients, and on the delicate bal-
ance that must be established between the efficacy of
transplantation and equity, within a context of scarcity.
The use of quantifiable data provided by personalized
medicine appears to have little impact on clinical judg-
ment and the relational aspect of the physician-patient
relationship, which is founded upon trust. In spite of the
growing reliance on scientific data, it is interesting to
note that the participants in this research want to keep
a place for clinical judgment. The interpretation of the
data must be made by a physician, drawing on his/her
own experience, judgment, medical expertise and knowl-
edge of the patient. Clinical judgment must remain; it is
a cornerstone of medical practice, which reconciles both
the humanistic and the scientific aspects of medicine. In
conclusion, research such as this is important in ensur-
ing the appropriate development of personalized medi-
cine within renal transplantation. This research clearly
indicates the importance of empirical approaches in
bioethics [41,42], which would provide assistance in
dealing with the ethical issues identified by practitioners
when personalized medicine is established in a clinical
setting. It is also essential to examine patients’ and
society’s views about the use of a personalized medicine
method in kidney transplantation, by using an empirical
approach. These views are currently under research
within the Interdisciplinary Group on the Predictors of
Immunological Risk.
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